Antibodies are the key molecules in human immune responses. Currently, the process of engineering antibodies for use in therapeutic drugs involves steps that are costly in time and resources.  Professor Charlotte Deane’s group at the University of Oxford’s Department of Statistics have developed a computational platform that can streamline the process.